Trogenix
2 known investors
Trogenix develops precision gene therapies for cancer using its Odysseus platform and Synthetic Super-Enhancer (SSE) technology, engineered DNA elements activated only in diseased cell states to selectively target and kill tumour cells while triggering an immune response. Its pipeline targets solid tumours, including a Phase I/II gene therapy (TGX-007) for glioblastoma, with potential applications in regenerative medicine.